Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Diffuse Large B-Cell Lymphoma | Research

Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study

Authors: Xiaoling Huang, Ying Wang, Zhenyu Huang, Xuzheng Chen, Qiuyan Lin, Haobo Huang, Liping Fan

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Apolipoprotein A1 (ApoA1) is a member of the apolipoprotein family with diverse functions. It is associated with the pathogenesis and prognosis of several types of tumors. However, the role of serum apolipoprotein A1 (ApoA1) in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. This study aimed to elucidate its influence on clinical outcomes in patients with DLBCL.

Methods

We retrospectively analyzed a cohort of 1583 consecutive DLBCL patients admitted to the Fujian Medical University Union Hospital between January 2011 and December 2021. 949 newly diagnosed DLBCL patients who met the inclusion criteria were enrolled for statistical analysis. Receiver operating characteristic curve analysis was performed to determine the optimal cut-off value for serum ApoA1 levels for prognostic prediction among patients with DLBCL. The correlations between serum ApoA1 levels and clinical and laboratory parameters were analyzed. Prognostic significance was analyzed using univariate and multivariate Cox proportional hazards models.

Results

Newly diagnosed patients with DLBCL demonstrated low serum ApoA1 levels (< 0.925 g/L), had more B symptoms, higher levels of serum lactate dehydrogenase (LDH) (>upper limit of normal), poorer performance status (Eastern Cooperative Oncology Group score of 2–4), higher percentage of advanced stage and non-germinal center B-cell (non-GCB) subtype, more cases of > 1 extranodal site, higher International Prognostic Index (IPI) score (3–5), and higher incidence of relapse or refractory diseases compared with those with high serum ApoA1 levels (≥ 0.925 g/L). Low serum ApoA1 levels were an independent adverse prognostic factor for overall survival (OS) but not progression-free survival (PFS).

Conclusions

Low serum ApoA1 levels were associated with poor treatment response and inferior survival in newly diagnosed patients with DLBCL.
Literature
1.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8.CrossRefPubMedPubMedCentral
2.
Shi Y, Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152–61.CrossRefPubMedPubMedCentral
3.
Liu P, Han Y, Jiang SY, He XH, Qin Y, Gui L, Zhou SY, Zhou LQ, Yang JL, Yang S, et al. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma. Chin Med J (Engl). 2019;132(15):1807–14.CrossRefPubMed
4.
Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, et al. Outcomes in patients with aggressive B-cell non-hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020;126(2):293–303.CrossRefPubMed
5.
6.
Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, Hosaka K, Lim S, Wu J, He X, et al. Cancer lipid metabolism confers antiangiogenic drug resistance. Cell Metab. 2018;28(1):104-117e105.CrossRefPubMed
7.
Cioce M, Canino C, Pass H, Blandino G, Strano S, Fazio VM. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. J Exp Clin Cancer Res. 2021;40(1):344.CrossRefPubMedPubMedCentral
8.
Barre FPY, Claes BSR, Dewez F, Peutz-Kootstra C, Munch-Petersen HF, Gronbaek K, Lund AH, Heeren RMA, Come C, Cillero-Pastor B. Specific lipid and metabolic profiles of R-CHOP-Resistant diffuse large B-Cell lymphoma elucidated by matrix-assisted laser desorption ionization mass spectrometry imaging and in vivo imaging. Anal Chem. 2018;90(24):14198–206.CrossRefPubMedPubMedCentral
9.
Fan L, Lin Q, Huang X, Fu D, Huang H. Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the Rituximab era: a retrospective analysis. BMC Cancer. 2021;21(1):1255.CrossRefPubMedPubMedCentral
10.
Gao R, Liang JH, Wang L, Zhu HY, Wu W, Cao L, Fan L, Li JY, Yang T, Xu W. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer. 2018;143(8):1884–95.CrossRefPubMed
11.
Wang F, Lu L, Chen H, Yue Y, Sun Y, Yan F, He B, Lin R, Gu W. Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of Rituximab. Ann Hematol. 2023;102(2):393–402.CrossRefPubMed
12.
Yu T, Luo D, Luo C, Xu-Monette ZY, Yu L. Prognostic and therapeutic value of serum lipids and a new IPI score system based on apolipoprotein A-I in diffuse large B-cell lymphoma. Am J Cancer Res. 2023;13(2):475–84.PubMedPubMedCentral
13.
Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: structure, function, mutations, and potential therapeutics. Biomed Pharmacother. 2022;154: 113634.CrossRefPubMed
14.
Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O. Apolipoproteins, lipids and risk of cancer. Int J Cancer. 2016;138(11):2648–56.CrossRefPubMed
15.
Cochran BJ, Ong KL, Manandhar B, Rye KA. APOA1: a protein with multiple therapeutic functions. Curr Atheroscler Rep. 2021;23(3):11.CrossRefPubMed
16.
Cine N, Baykal AT, Sunnetci D, Canturk Z, Serhatli M, Savli H. Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncol Rep. 2014;32(3):1078–86.CrossRefPubMed
17.
Gumilas NSA, Harini IM, Ernawati DA, Indriani V, Novrial D, Kurniawan DW. Potential of apolipoprotein A1 (ApoA1) for detecting liver cirrhosis and Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2022;23(6):2001–8.CrossRefPubMedPubMedCentral
18.
He Y, Han SB, Liu Y, Zhang JJ, Wu YM. Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer. BMC Cancer. 2022;22(1):411.CrossRefPubMedPubMedCentral
19.
Lin CH, Huang RY, Lu TP, Kuo KT, Lo KY, Chen CH, Chen IC, Lu YS, Chuang EY, Thiery JP, et al. High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. NPJ Breast Cancer. 2021;7(1):88.CrossRefPubMedPubMedCentral
20.
Liu JX, Yuan Q, Min YL, He Y, Xu QH, Li B, Shi WQ, Lin Q, Li QH, Zhu PW, et al. Apolipoprotein A1 and B as risk factors for development of intraocular metastasis in patients with breast cancer. Cancer Manag Res. 2019;11:2881–8.CrossRefPubMedPubMedCentral
21.
Ma J, Bai Y, Liu M, Jiao T, Chen Y, Yuan B, Liu B, Zeng L, Ming Z, Li W, et al. Pretreatment HDL-C and ApoA1 are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with TKI. Thorac Cancer. 2022;13(8):1126–35.CrossRefPubMedPubMedCentral
22.
Pan Y, Ye Z, Ling Y, Kong L, Wang C, Chen G, Wan D, Chen M, Hu D. The apolipoprotein B and apolipoprotein A-I ratio serves as a strong prognostic factor for the overall survival of patients with colorectal cancer. Front Oncol. 2022;12:1089688.CrossRefPubMed
23.
Sun Y, Ren D, Yang C, Yang W, Zhao J, Zhou Y, Jin X, Wu H. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Biochim Biophys Acta Mol Basis Dis. 2021;1867(11): 166213.CrossRefPubMed
24.
Zeng W, Xiong G, Hua L, Hu Y, Guo X, Peng X. APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome. Sci Rep. 2022;12(1):12406.CrossRefPubMedPubMedCentral
25.
Yang Z, Zhang D, Sima X, Fu Y, Zeng H, Hu Z, Hou J, Pan Y, Zhang Y, Zhou Z, et al. Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma. Int Immunopharmacol. 2023;115: 109687.CrossRefPubMed
26.
Montero-Calle A, Gomez de Cedron M, Quijada-Freire A, Solis-Fernandez G, Lopez-Alonso V, Espinosa-Salinas I, Pelaez-Garcia A, Fernandez-Acenero MJ, Ramirez de Molina A, Barderas R. Metabolic reprogramming helps to define different metastatic tropisms in Colorectal Cancer. Front Oncol. 2022;12: 903033.CrossRefPubMedPubMedCentral
27.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2007;25(5):579–86.CrossRef
28.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, et al. Non-hodgkin’s lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013;11(3):257–72 (quiz 273).CrossRefPubMed
29.
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, et al. NCCN guidelines Insights: Non-hodgkin’s Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067–79.CrossRefPubMed
30.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, et al. NCCN guidelines insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650–61.CrossRefPubMed
31.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, et al. NCCN Clinical Practice Guidelines in Oncology: non-hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288–334.CrossRefPubMed
32.
Wang M, Fang X, Wang X. Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;61(4):763–75.CrossRefPubMed
33.
Risueno A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew CP, Nowakowski GS, Maurer MJ, Cerhan JR, et al. Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent. Blood. 2020;135(13):1008–18.PubMedPubMedCentral
34.
El Sayed R, El Darsa H, Kort J, Al Chami F, Ibrahim A, Charafeddine M, Bazarbachi A, Abou Dalle I, El Cheikh J. Safety and Efficacy of replacing vindesine with vincristine in R-ACVBP regimen for the treatment of large B cell lymphomas. Clin Lymphoma Myeloma Leuk. 2021;21(10):711–9.CrossRefPubMed
35.
Cherng HJ, Westin J. Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;62(6):1302–12.CrossRefPubMedPubMedCentral
36.
Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–8.CrossRefPubMed
37.
Sagini K, Urbanelli L, Buratta S, Emiliani C, Llorente A. Lipid biomarkers in Liquid biopsies: Novel opportunities for Cancer diagnosis. Pharmaceutics 2023;15(2):437.
38.
Li J, Zhang S, Chen S, Yuan Y, Zuo M, Li T, Wang Z, Liu Y. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas. Front Immunol. 2023;14: 1021678.CrossRefPubMedPubMedCentral
39.
Kopecka J, Trouillas P, Gasparovic AC, Gazzano E, Assaraf YG, Riganti C. Phospholipids and cholesterol: inducers of cancer multidrug resistance and therapeutic targets. Drug Resist Updat. 2020;49: 100670.CrossRefPubMed
40.
41.
Oberle R, Kuhrer K, Osterreicher T, Weber F, Steinbauer S, Udonta F, Wroblewski M, Ben-Batalla I, Hassl I, Korbelin J, et al. The HDL particle composition determines its antitumor activity in pancreatic cancer. Life Sci Alliance. 2022;5(9):e202101317.
Metadata
Title
Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study
Authors
Xiaoling Huang
Ying Wang
Zhenyu Huang
Xuzheng Chen
Qiuyan Lin
Haobo Huang
Liping Fan
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11818-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China

Research

Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy

Research

Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study

Research

Impact of the COVID-19 pandemic in childhood and adolescent cancer care in northern Tanzania: a cross-sectional study

Matters Arising

Comment on “A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer”

Research

Mechanism of intestinal microbiota disturbance promoting the occurrence and development of esophageal squamous cell carcinoma——based on microbiomics and metabolomics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits